Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin’s Lymphoma compared with conventional treatment in India: a Markov-model based analysis

References

• Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163–168. doi:10.1200/JCO.2013.53.1194
   PubMed Web of Science ®Google Scholar
• Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin’s lymphoma. N Engl J Med. 2009;361(24):2390–2391. doi:10.1056/NEJMc0906731
   PubMed Web of Science ®Google Scholar
• Hokland P, Shah M, David K, et al. How I treat advanced Hodgkin lymphoma – a global view. Br J Haematol. 2020;190(6):837–850. doi:10.1111/bjh.16587
   PubMed Web of Science ®Google Scholar
• Spinner MA, Advani RH, Connors JM, et al. New treatment algorithms in Hodgkin lymphoma: too much or too little? Am Soc Clin Oncol Educ Book. 2018;38:626–636. doi:10.1200/EDBK_200679
   PubMedGoogle Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for HODGKIN’S lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212. doi:10.1056/NEJMoa1100340
   PubMed Web of Science ®Google Scholar
• Ganesan P. Interim-response-adapted therapy in advanced Hodgkin’s lymphoma: current status. Indian J Med Paediatr Oncol. 2019;40(04):566–569. doi:10.4103/ijmpo.ijmpo_276_19
   Google Scholar
• Lang N, Crump M. PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. Ther Adv Hematol. 2020;11:2040620720914490. doi:10.1177/2040620720914490
   Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi:10.1056/NEJMoa1510093
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462. doi:10.1200/JCO.2017.75.2543
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the german hodgkin study group. Lancet. 2017;390(10114):2790–2802. doi:10.1016/S0140-6736(17)32134-7
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019 Feb;20(2):202–215. doi:10.1016/S1470-2045(18)30784-8
   PubMed Web of Science ®Google Scholar
• Ansell SM, Radford J, Connors JM, et al. Brentuximab vedotin for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;387(4):310–320. doi:10.1056/NEJMc1802363
   Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 gruppo italiano per lo studio dei linfomi trial. J Clin Oncol. 2009;27(5):805–811. doi:10.1200/JCO.2008.17.0910
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: a study by fondazione italiana linfomi. J Clin Oncol. 2016;34(11):1175–1181. doi:10.1200/JCO.2015.62.4817
   PubMed Web of Science ®Google Scholar
• Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34(17):2028–2036. doi:10.1200/JCO.2015.64.5648
   PubMed Web of Science ®Google Scholar
• Patrice PC, Abvd 8. (Cycles) versus BEACOPP (4 escalated cycles = > 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. 2012.
   Google Scholar
• Ganesan P, Rajendranath R, Kannan K, et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced hodgkin’s lymphoma. Ann Oncol. 201;26(6):1170–1174. doi:10.1093/annonc/mdv077
   PubMed Web of Science ®Google Scholar
• Luminari S, Fosså A, Trotman J, et al. Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy. Blood 2022; 140 (Supplement 1): 766–767. doi: https://doi.org/10.1182/blood-2022-162780
   Web of Science ®Google Scholar
• Sibon D, Morschhauser F, Resche-Rigon M, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016;101(4):474–481. doi:10.3324/haematol.2015.136408
   PubMed Web of Science ®Google Scholar
• Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed/refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839–1845. doi:10.3109/10428194.2014.970542
   PubMed Web of Science ®Google Scholar
• Huntington SF, von Keudell G, Davidoff AJ, et al. Cost-Effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma. J Clin Oncol. 2018;36(33):JCO1800122. doi:10.1200/JCO.2018.36.15_suppl.6609
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. doi:10.1186/1477-7525-6-84
   PubMed Web of Science ®Google Scholar
• Chief Ministers Comphrehensive Health Insurance Scheme. https://www.cmchistn.com/prate.php?category=MEDICAL%20ONCOLOGY.
   Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791–1799. doi:10.1016/S0140-6736(11)61940-5
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548–4554. doi:10.1200/JCO.2008.19.8820
   PubMed Web of Science ®Google Scholar